menu
    • menu

    Company profile for Elixirgen Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Elixirgen Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines. The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. Elixirgen Therapeutics is located in the Science + Tec...
    Elixirgen Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines. The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics' scientists to conduct research at state-of-the-art facilities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Elixirgen TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    855 N. Wolfe St. Suite 619 Baltimore, MD 21205
    Telephone
    Telephone
    (443) 869-5420
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://elixirgentherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elixirgen Therapeutics Publishes Early Results on Telomere Elonga
    Elixirgen Therapeutics Publishes Early Results on Telomere Elonga

    25 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/25/3032162/0/en/Elixirgen-Therapeutics-Publishes-Early-Results-Showing-Telomere-Elongation-in-First-Gene-Therapy-Trial-for-Telomere-Biology-Disorders.html

    GLOBENEWSWIRE
    25 Feb 2025
    Share Share
    Elixirgen Gets FDA Orphan Drug Nod For EXG-34217 In TBD
    Elixirgen Gets FDA Orphan Drug Nod For EXG-34217 In TBD

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/20/3030085/0/en/Elixirgen-Therapeutics-Granted-FDA-Orphan-Drug-Designation-for-EXG-34217-for-Treatment-of-Telomere-Biology-Disorders.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    Elixirgen Gets RMAT Designation for EXG-34217 in Telomere Disorders
    Elixirgen Gets RMAT Designation for EXG-34217 in Telomere Disorders

    13 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/13/3025885/0/en/Elixirgen-Therapeutics-Granted-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-EXG-34217-for-Treatment-of-Telomere-Biology-Disorders.html

    GLOBENEWSWIRE
    13 Feb 2025
    Share Share
    Elixirgen Gets Rare Pediatric Disease Tag For EXG-34217
    Elixirgen Gets Rare Pediatric Disease Tag For EXG-34217

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952915/0/en/Elixirgen-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-for-EXG-34217-in-Dyskeratosis-Congenita-and-Related-Telomere-Biology-Disorders.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology
    Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology

    04 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/04/2839511/0/en/Elixirgen-Therapeutics-Presents-Preclinical-Data-with-Bobcat-mRNATM-Technology-in-Duchenne-Muscular-Dystrophy-at-the-2024-Muscular-Dystrophy-Association-MDA-Clinical-Scientific-Con.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003
    Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003

    16 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/16/2760576/0/en/Elixirgen-Therapeutics-Announces-Promising-Phase-1-2-Data-on-EXG-5003-a-Controllable-Self-Replicating-RNA-c-srRNA-Vaccine-Against-SARS-CoV-2.html

    GLOBENEWSWIRE
    16 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search